Axcella Health Inc. is a biotechnology company that specializes in developing novel therapeutic solutions through a pioneering approach known as "endogenous metabolic modulators" (EMMs). Established in 2008 and headquartered in Cambridge, Massachusetts, the company is dedicated to transforming the treatment landscape for various diseases by harnessing the body's own metabolic pathways.
At the heart of Axcella's approach is the concept of EMMs, which are naturally occurring molecules that play essential roles in maintaining health and metabolic balance. The company's research revolves around identifying specific EMMs and leveraging their potential to address underlying metabolic dysregulations associated with diseases.
Axcella's therapeutic focus spans a range of medical conditions, including liver diseases, muscle-related disorders, and metabolic disorders. By harnessing the power of EMMs, the company aims to develop targeted interventions that modulate cellular pathways and restore metabolic balance, ultimately leading to improved patient outcomes.
The company's lead product candidate, AXA1665, is designed to address non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease. AXA1665 aims to regulate lipid metabolism and inflammation, key factors in the development of NASH, and potentially offer a new approach to treating this prevalent and serious condition.
Axcella's innovative approach has garnered attention for its potential to revolutionize the field of therapeutics. By utilizing endogenous metabolic pathways, the company seeks to provide treatments that are more targeted, natural, and holistic, addressing the root causes of diseases rather than just their symptoms.